Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive breast cancer. However, about 70% of all treated patients will experience relapse or disease progression. This may be related to an insufficient targeting of the CD44(high)CD24...

Descripción completa

Detalles Bibliográficos
Autores principales: Diessner, J, Bruttel, V, Stein, R G, Horn, E, Häusler, S F M, Dietl, J, Hönig, A, Wischhusen, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973200/
https://www.ncbi.nlm.nih.gov/pubmed/24675467
http://dx.doi.org/10.1038/cddis.2014.115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973200/
https://www.ncbi.nlm.nih.gov/pubmed/24675467
http://dx.doi.org/10.1038/cddis.2014.115

Ejemplares similares